Tandem Diabetes Q4 sales $210M (+25% YoY); FY2021 sales $703M (+41%); 2022 guide $845-860M

TANDEM DIABETES CARE INC

2021-FY EPS reported $0.24 revenue$702,799,000

Full-year 2021 sales $702.8M (+41% YoY); net income $15.6M vs loss $34.4M in 2020.
Q4 2021 sales $210.0M (+25% YoY); gross margin 54%; operating income $12.7M.
2022 guidance: sales $845-860M (20-22% growth); adjusted EBITDA margin 14-15% of sales.
Worldwide pump shipments 128,312 in 2021, up 41% YoY.
Appointed David Berger as EVP, COO effective Feb 3, 2022; board chair retainer cut from $115K to $50K.

item 2.02 item 2.0 item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

David B. Berger

Executive Vice President, Chief Operating Officer and Assistant Secretary

TNDM · TANDEM DIABETES CARE INC

Effective: 2022-02-03
Filed: February 22, 2022, 6:59 PM ET

On February 3, 2022, the Board of Directors appointed David B. Berger, age 52, to serve as the Company’s Executive Vice President, Chief Operating Officer and Assistant Secretary.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

David B. Berger was appointed as Executive Vice President, Chief Operating Officer and Assistant Secretary at TANDEM DIABETES CARE INC.

Action: appointed
Role: Executive Vice President, Chief Operating Officer and Assistant Secretary

Exact text from the filing

On February 3, 2022, the Board of Directors appointed David B. Berger, age 52, to serve as the Company’s Executive Vice President, Chief Operating Officer and Assistant Secretary.

View on SEC.gov

TANDEM DIABETES CARE INC filing history →

Source: SEC EDGAR

accession 0001438133-22-000020

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.